US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches

 
• By Sue Sutter and Mandy Jackson

Amgen and Allergan’s launch of the first biosimilars to Roche/Genentech’s Avastin and Herceptin may not face the same commercial dynamics that have stymied biosimilars in other therapeutic areas, but uptake could depend upon oncologists’ comfort level in prescribing the follow-on agents.

Apollo-11
50 years after Apollo 11 blasted off for the moon, Amgen and Allergan have their own landmark launches to boast about. • Source: Shutterstock

More from Business

More from Scrip